Effect of Drug in Glucocorticoid-induced Bone Loss Treatment

The effectiveness of denosumab and risedronate in reducing the glucocorticoid-induced bone loss were tested. Denosumab was found effective by increasing the bone density in the lower spine and can be useful in osteoporosis treatment.

A new study analyzes the effectiveness of drugs in reducing the glucocorticoid-induced bone loss. The findings of the study are published in the journal The Lancet Diabetes & Endocrinology.

About one in every 100 people in the //world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.

Osteoporosis-Causes-Symptoms-Diagnosis-Treatment-FAQs
Osteoporosis is a bone disease that leads to an increased risk of fractures. The bone mass is reduced and the bones are porous, thereby resulting in weakness of the skeletal system of the body.

‘The effectiveness of denosumab and risedronate in reducing the glucocorticoid-induced bone loss were tested. After a 12-month study, denosumab was found superior to risedronate by increasing the bone density in the lower spine.’

The study was headed by Kenneth Saag, M.D., the Jane Knight Lowe Professor of Medicine at the University of Alabama at Birmingham.

Saag and colleagues compared the monoclonal antibody denosumab against a standard treatment for glucocorticoid-induced secondary osteoporosis, the bisphosphonate risedronate. In the 12-month results of their 24-month study, they have found that denosumab was superior to risedronate, as measured by increased bone density in the lower spine.

"To our knowledge, ours is the first large, randomized controlled trial of denosumab in patients with glucocorticoid-induced osteoporosis who were either prevalent glucocorticoid users or newly initiating glucocorticoid therapy," they wrote. "Denosumab could be a useful addition to the treatment armamentarium for glucocorticoid-induced osteoporosis."

About Lifestyle and Osteoporosis
Encyclopedia section of medindia briefly explains about Lifestyle and Osteoporosis

The double-blind study enrolled 795 patients at 79 health care centers in Europe, Latin America, Asia and North America. Of these, 505 were glucocorticoid-continuing patients who had received glucocorticoids for at least three months, and 290 were glucocorticoid-initiating patients who had received glucocorticoids for less than three months.

Patients were randomly assigned to one of two groups. The denosumab group got a shot of denosumab underneath the skin every six months and took a placebo pill every day. The risedronate group got a placebo shot every six months and took oral risedronate every day.

Boost Bone Health in 12 Simple Ways
More than 6 cups of coffee a day may harm bone health. Fish and olive oil may increase bone density.

Besides the superior lumbar spine bone density with denosumab after 12 months, researchers also found that denosumab was superior to risedronate for bone density measured in the total hip and at the neck of the femur, the large bone of the thigh.

The two treatment groups had similar safety profiles.

Dairy Products and Vitamin D Supplements Protect Against Osteoporosis in Older Adults
Older adults who consume dairy products along vitamin D supplements are less likely to suffer from bone loss and osteoporosis, finds a study.

The researchers note that the study compared denosumab with risedronate, so the relative performance of denosumab compared with osteoporosis treatments besides risedronate has not yet been established.

Source-Eurekalert